CLINICAL_TRIALS
trial_result
· 2012-10-02
Clinical Trial Update: A Phase 3 Efficacy Study Of Dimebon In Patients With Moderate To Severe Alzheimer's Disease [Phase 3]
Summary
Pfizer terminated a Phase 3 efficacy study of Dimebon (latrepirdine) for Alzheimer's disease; results were posted in 2012.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Pfizer | Conditions: Alzheimer Disease | Phase 3 | Status: TERMINATED | Results posted: 2012-10-02